HeartFlow (HTFL) Q2 FY26 earnings call

HeartFlow delivered an outstanding second quarter, with accelerating revenue growth driven by strong performance in both its Plaque and FFRCT offerings. The company raised its full-year revenue and gross margin guidance, reflecting confidence in its commercial momentum, innovation pipeline, and expanding market opportunities, particularly in the high-risk asymptomatic segment. Management remains focused on achieving cash flow profitability by mid-2028, supported by operating leverage and AI-enabled efficiencies.